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Abstract 39 
We conducted in Kenya a mixed-methods randomised controlled trial (RCT) of a 40 
nurse-led palliative care intervention integrated with anti-retroviral therapy (ART) 41 
provision for the management of HIV. Here we report qualitative findings showing 42 
increased resistance to HIV-associated stigma among trial participants. A mixed 43 
method design was chosen to enable identification of the active ingredients of the 44 
intervention and exploration of participants’ experiences of receiving the intervention. 45 
The RCT was conducted from July 2011 to November 2012 in a community hospital 46 
in the city of Mombasa, Kenya, with a sample of 120 adults with HIV on ART. Thirty 47 
participants were purposively selected to take part in a qualitative exit interview, 48 
based on study arm and mental health outcome.  49 
Inductive thematic analysis revealed increased resistance to HIV-associated stigma 50 
in both the intervention and control groups. Specifically, patients in both groups 51 
described benefit from the social support, compassionate care, and open and 52 
respectful communication they received through study participation. Participants 53 
described improved self-image, increased access to social agency, and increased 54 
resistance to HIV-associated stigma. Our findings suggest that there is potential to 55 
increase resistance to stigma through simple mechanisms of support, compassion, 56 
and improved communication in routine care. The self-reported impact of trial 57 
participation on stigma also has implications for future trials in populations in 58 
resource-constrained settings where stigma is common.  59 
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Introduction 62 
Stigma was defined by Goffman in 1963 as a mark of social disgrace, where the 63 
stigmatised are excluded from social acceptance and are socially devalued 64 
(Goffman, 1963). Although commonly understood at the individual level (Herek, 65 
Saha, & Burack, 2013a), or the macro-societal level (Parker & Aggleton, 2003), an 66 
appreciation of both acknowledges how social processes become part of a 67 
stigmatised other’s identity making resistance at an individual level very difficult 68 
(Catherine Campbell & Deacon, 2006). The persistence of HIV associated stigma, is 69 
a threat to progress in the control of HIV internationally (Stangl & Grossman, 2013), a 70 
barrier to testing (Dapaah & Senah, 2016), prevention of mother-to-child transmission 71 
(Turan & Nyblade, 2013), and, once diagnosis is confirmed, stigma remains a barrier to 72 
PLWH accessing adequate healthcare (Bogart et al., 2013; Dasgupta, Sullivan, Dasgupta, 73 
Saha, & Salazar, 2013). It is also associated with non-adherence to antiretroviral 74 
therapy (ART), increasing the risk of viral resistance (Mhode & Nyamhanga, 2016; 75 
Sweeney & Vanable, 2016).  76 
Community members often distance themselves from PLWH due to stigma (C. 77 
Campbell, Foulis, Maimane, & Sibiya, 2005; Visser & Sipsma, 2013), denying their own risk 78 
of contracting HIV, putting themselves at increased risk of transmission and delayed 79 
diagnosis (Nyblade et al., 2003). Among PLWH, the social ramifications of disclosure 80 
increase the risk of transmission through reluctance to openly take medications or 81 
negotiate condom use with a sexual partner (Mbonu, van den Borne, & De Vries, 2009; 82 
Turan & Nyblade, 2013).  83 
In addition to these public health concerns, there is evidence that people 84 
experiencing HIV-associated stigma report less healthcare utilization, and poorer 85 
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physical health (Bennett, Traub, Mace, Juarascio, & O’Hayer, 2016; Herek, Saha, & Burack, 86 
2013b). HIV-associated stigma also manifests as social isolation and rejection (C. 87 
Campbell et al., 2005; Owolabi et al., 2012), increasing depression (Palmer et al., 2011; 88 
Sumari-de Boer, Sprangers, Prins, & Nieuwkerk, 2012), anxiety (Adewuya et al., 2009) and 89 
low self-esteem (Visser & Sipsma, 2013). A recent study suggests that this relationship 90 
between HIV-associated stigma and psychological well-being may be mutually 91 
reinforcing (Miller et al., 2016).  92 
The international community struggles to identify stigma reduction interventions that 93 
are effective for HIV-related health outcomes (Stangl, Lloyd, M Brady, Holland, & 94 
Baral, 2013). Studies are often methodologically weak due to predominant use of 95 
locally-created and/or un-validated outcome measures, which inhibit interpretation 96 
and comparison across studies (Sengupta, Banks, Jonas, Miles, & Smith, 2011; 97 
Stangl et al., 2013).  98 
HIV-associated stigma also presents high costs for society (direct and indirect effects 99 
of stigma reduction have been valued at a potential $1000 per point on the Berger 100 
Stigma scale) (Brent, 2016).  101 
We conducted a randomised controlled trial (RCT) of a nurse-led palliative care 102 
intervention for PLWH established on ART in Mombasa, Kenya (Lowther et al., 2012, 103 
2014, 2015). In qualitative exit interviews, the themes of stigma, resistance to stigma, 104 
and the effects of participation in the research, emerged inductively as highly salient 105 
to participants. In this paper, we aim to describe experiences of stigma and stigma 106 
resistance among PLWH enrolled in the trial, and to draw out implications for clinical 107 
practice and research.  108 
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Materials and methods 109 
The Treatment Outcomes in Palliative Care (TOPCare) study was an RCT of a 110 
nurse-led, integrated palliative care intervention for HIV positive patients conducted 111 
in a clinic in Mombasa, Kenya. The trial had an embedded qualitative component 112 
with a sequential, explanatory design (Ivankova, Creswell, & Stick, 2006). Study 113 
methodology is reported elsewhere (Lowther et al., 2012), as are details of 114 
recruitment, follow up and missing data (Lowther et al., 2014), and results of the trial 115 
(Lowther et al., 2015). We found the intervention had significant positive effect in terms 116 
of mental health and well-being, but no effect on pain or physical outcomes (Lowther 117 
et al., 2015).  118 
The intervention consisted of 4 months of palliative care integrated into patients’ 119 
routine HIV outpatient care. It was delivered by two experienced HIV clinic nurses 120 
who received two weeks’ specialist training in palliative care from the Kenyan 121 
Hospice and Palliative Care Association and clinical support and mentoring from 122 
local hospice nurses. The training covered pain management, symptom 123 
management, nutrition, psychosocial and spiritual assessment and care, breaking 124 
bad news, ethical and legal issues, and bereavement. Participants in the intervention 125 
arm received a minimum of 7 appointments (approximately 45 minutes long) with 126 
one of the two intervention nurses. The nurse delivered person-centred care which 127 
included a holistic assessment of emotional, spiritual, social and physical well-being, 128 
patients’ understanding of HIV, and ability to maintain treatment adherence. This 129 
assessment informed care delivery, with hospice referral for complex cases of pain 130 
and symptom management. Control arm participants received standard care in the 131 
Comprehensive Care Clinic (CCC) at the study site, which consisted of monthly 132 
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appointments usually lasting 5-7 minutes. They were seen by HIV clinic nurses with 133 
similar levels of experience but without the additional training. 134 
Sampling  135 
Participants who met the inclusion criteria for the wider trial were aged ≥18, HIV 136 
positive and on ART for more than one month, and reported moderate to severe pain 137 
or symptoms lasting at least 2 weeks, as measured by the African Palliative Care 138 
Association Palliative Outcome Scale (APCA POS (Harding et al., 2010)). The sub-139 
sample recruited to the qualitative component of the study was purposively selected 140 
based on study arm allocation and individual quantitative response to participation in 141 
the trial. Participants from the intervention arm were over-sampled (10 control /20 142 
intervention) to enable in depth exploration of the active ingredients and mechanism 143 
of action of the intervention (data to be reported elsewhere). Sampling was in line 144 
with a sequential explanatory mixed methods design: we purposively selected 145 
participants to achieve a maximum variation sample based on individuals’ clinical 146 
response to the intervention. Response was measured using the Medical Outcomes 147 
Survey – HIV Mental Health Summary Score (MOS-HIV MHSS), the mental health 148 
subscale of a well-validated, disease-specific quality of life measure (Wu, 1999). A 149 
change of 10 points on the MOS-HIV MHSS is considered clinically significant (Wu, 150 
1999). Participants were categorised as “improving” if they improved by ≥10 points 151 
during the four-month study period, “static” if there was <10 points change in either 152 
direction, and “deteriorating” if they decreased by >10 points over the study period.  153 
A sample size of thirty qualitative interviews was chosen to balance opportunity for 154 
data saturation with feasibility of in-depth analysis (Sandelowski, 1995).  155 
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Data collection 156 
Data collection in both groups involved five quantitative data collection appointments 157 
at monthly intervals, with selected participants invited to take part in a qualitative 158 
interview from 1-8 months post trial exit.  159 
The same Kenyan researcher (NG) who collected the quantitative data throughout 160 
the RCT conducted the qualitative exit interviews. The researcher was skilled and 161 
experienced in qualitative research, provided with study-specific training, and 162 
bilingual in English and Swahili. The interviews lasted approximately 45 minutes, and 163 
were guided by a semi-structured topic guide developed by the study group. The 164 
topic guide included questions about participants’ physical, psychological, social and 165 
spiritual well-being before, during and after the study, in line with the holistic nature 166 
of the palliative care approach (WHO, 2013). Participants were also asked about their 167 
experiences of participating in the study, and, if allocated to the intervention arm, 168 
their perceptions of the differences between the two models of care (intervention vs 169 
standard care). 170 
The interviews were conducted in a private location at the study site in either 171 
English, Swahili or both, depending on participant preference. Participants were 172 
welcomed into the study setting, and given refreshments to demonstrate hospitality 173 
and respect. The interviews were digitally recorded, transcribed and translated into 174 
English (where needed) by an experienced translator. Translations were quality 175 
checked by the researcher against the interview recordings, and amended if 176 
inaccuracies or errors were identified. 177 
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Analysis 178 
Transcripts were analysed thematically using a combination of deductive and 179 
inductive coding (Braun & Clarke, 2006). Deductive themes were identified according 180 
to the domains of well-being integral to palliative care (physical, psychological, social 181 
and spiritual), while additional themes emerged inductively. Themes were defined as 182 
codes or collections of codes containing elements which represented a patterned 183 
response or concept (Barbour, 2013). Following Barbour, the following questions 184 
were posed to identify themes, with constant reference to the study objectives: 185 
“Which codes are repeated? How do they relate to each other? Do these codes 186 
relate as sub-themes or associates in that they occur simultaneously?” (Barbour, 187 
2013). Once identified, themes were organised hierarchically into major themes and 188 
sub-themes, according to their meaning and relationship to each other, to structure 189 
and reduce the volume of data. Major themes were those with high levels of salience 190 
and significance, in terms of understanding the therapeutic aspects of the 191 
intervention and their repetition across the dataset. Analysis was managed using 192 
NVivo 9 software. Findings are presented using anonymised illustrative quotes, 193 
annotated with the participant’s gender, age and intervention arm (Tables 2 and 3, 194 
cross-referenced in the text).  195 
Ethics 196 
Ethical approval was provided by King’s College London Research Ethics Committee 197 
(BDM/10/11-31) and the Kenyan Medical Research Institute (KEMRI/RES/7/3/1). All 198 
patients gave written informed consent (if the participant was unable to read or write, 199 
the information sheet was read aloud and a thumb print given to indicate consent). 200 
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Results 201 
Sample characteristics 202 
30 participants were interviewed; no one approached declined. Participants were 203 
similar to the wider trial sample in terms of clinical and demographic characteristics 204 
(Table 1). Mean age was 39.1, with a mean of 2.4 children and 3.2 financial 205 
dependants. Most were women (80%, n=24), and two-thirds (67.7%, n=20) 206 
completed primary school as their highest educational attainment. Interviews were 207 
conducted from one to eight months after trial exit (mean 4.2 months). The research 208 
team judged that data saturation was reached in that no new themes emerged from 209 
the analysis of later interviews.  210 
[INSERT TABLE 1 NEAR HERE] 211 
Findings 212 
Stigma arose inductively in the data as an important characteristic of participants’ 213 
experience of living with HIV, described by 25 of the 30 participants. Findings 214 
regarding stigma are presented in two themes: experience of HIV-associated stigma, 215 
and effects on HIV-associated stigma of participation in the trial. 216 
Experience of HIV-associated stigma (Table 2) 217 
When asked to describe their well-being before study participation, many participants 218 
described the experience of stigma indirectly, in terms of a fear of disclosure of their 219 
HIV diagnosis. They anticipated that this would lead to being shamed, socially 220 
isolated or discriminated against (quote 1). Participants reported hiding their status 221 
behind diagnoses which were more socially acceptable to their networks, for 222 
example saying they had tuberculosis (TB). The HIV positive diagnosis led some 223 
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participants to self-hatred and suicidal ideation. One participant described how 224 
internalised stigma, from cultural norms associating HIV with immorality, created an 225 
identity crisis (quote 2). Once they disclosed their HIV status to others, some 226 
participants reported experiencing anger and blame from their families and other 227 
community members (quote 3).  228 
Experiencing this enacted stigma or discrimination against PLWH, either directly or 229 
vicariously, discouraged participants from disclosing their status, which led to 230 
increased isolation and suffering. Social isolation was a major cause of sadness; 231 
friends from before they were diagnosed had left, increasing their sense of 232 
vulnerability and isolation (quote 4)  233 
[INSERT TABLE 2 NEAR HERE] 234 
Effects of participation in research on HIV-associated stigma (Table 3) 235 
During the counselling received in clinical appointments, intervention participants 236 
were encouraged by the study nurses to see themselves as normal, just like any 237 
other person. This was reported to improve self-esteem, self-image and acceptance, 238 
and help participants resist internalised stigma (quotes 5-7).  Some intervention arm 239 
participants described dramatic changes in their outlook, from suicidal to positive 240 
(quote 8). However, the beneficial effects of participation also extended to those 241 
PLWH in the control arm, with both groups of participants describing the therapeutic 242 
effects of their interactions with the study team (quotes 9, 10)  243 
Participants built a trusting relationship with the researcher who administered the 244 
study questionnaires, owing to the compassion they witnessed, and her non-245 
judgemental and open communication style. They described how this way they were 246 
treated, enabled them to rebuild a positive self-image (quotes 11, 12). This change in 247 
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self-regard was often described as a shift in seeing themselves as normal rather 248 
than abnormal, and worthy of respect, social interest and engagement (quotes 13, 249 
14). Participants described how, through this growth in self-esteem, they were more 250 
able to reject stigmatising messages, and became confident in disclosing their HIV 251 
positive status to their close communities (quote 15). Being treated as a normal 252 
person by a health care practitioner was in stark contrast to the advice received by 253 
one participant attending the standard clinic, who reported she was advised to 254 
‘behave normally’ when she received her diagnosis, in case people realised that she 255 
was HIV positive (quote 16).  256 
One of the most powerful aspects of participation in reducing internalised stigma was 257 
being given the space and permission to talk (quotes 17, 18). Some participants 258 
clearly attributed the effect to the process of completing the outcome measurements 259 
(quotes 19, 20). Because of participation in the study and the support they received 260 
through attending data collection appointments, some participants made concrete 261 
changes to their social situations (quote 21). Others became activists in less public 262 
ways, making themselves available to others for counselling and support, particularly 263 
those who had recently received their diagnosis. They described having the 264 
confidence and self-belief to act normally, interacting with their communities 265 
accordingly, and ignoring the stigmatising responses they had previously anticipated 266 
and feared. These newly created identities as ‘activists’ were socially acceptable and 267 
added purpose to participants’ lives participants (quotes 22, 23).  268 
[INSERT TABLE 3 NEAR HERE] 269 
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Discussion 270 
The findings of this study demonstrate the therapeutic value of a relationship 271 
characterised by compassionate care, social support, and open and non-272 
judgemental communication. While intervention group participants described benefit 273 
from their appointments with the study nurse, participants in both groups described 274 
the way that simply participating in the trial’s data collection procedures helped them 275 
to increase their resistance to the stigma associated with HIV.  276 
The researcher completed standardised patient reported outcome measures with 277 
each participant at regular intervals over a four-month time-period. She had no 278 
therapeutic remit or training, yet participants clearly described therapeutic benefit, 279 
including increasing ability to resist stigma. We can see two possible reasons for 280 
this. Firstly, the act of being asked questions about their well-being and problems 281 
may have served to acknowledge their importance. Secondly, being accepted and 282 
treated with respect may have helped patients renegotiate a positive self-identity. 283 
This second hypothesis is supported by other studies of HIV-associated stigma 284 
(Goudge, Ngoma, Manderson, & Schneider, 2009; Soskolne, 2003). In a study in South 285 
Africa, women living with HIV described how, given time, they were able to negotiate 286 
a new positive self-identity which helped them cope with anxiety and the stigma of 287 
their HIV diagnosis (Soskolne, 2003). The work of Goudge et al. (2009) describes the 288 
crucial role of social support – the very thing lacking when stigma is present and 289 
powerful - in this process (Goudge et al., 2009). They found that through social 290 
support, PLWH were able to express their emotions, make sense of their diagnosis 291 
and move towards a problem-solving approach toward managing their health, 292 
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whereas those with less support were less able to adjust and cope (Goudge et al., 293 
2009).  294 
The shift observed in our participant group can also be understood through the lens 295 
of shame and shame resistance theories. Van Vliet’s theory of shame resistance 296 
states that to improve the affected person’s self-concept individuals must undergo a 297 
process of reconstruction, rebuilding a new identity in response to a shaming 298 
experience (Van Vliet, 2008). She describes the five sub-processes this involves: 299 
connecting, refocusing, accepting, understanding and resisting (Van Vliet, 2008). 300 
These sub-processes appear to mirror our participants’ descriptions of their 301 
experience of participating in the trial. Connecting and refocusing are described 302 
when patients talk of the social support they received from the research team. 303 
Acceptance can be seen in their descriptions of learning to accommodate their HIV 304 
status, in part through the acceptance they experienced from the research team. 305 
Participants receiving the intervention described being treated as normal people, told 306 
that they were normal and advised that should treat themselves accordingly, as 307 
particularly potent aspects of the intervention. Central to acceptance was coming to 308 
understand that anyone, even morally ‘good’ people, can get HIV. The final sub-309 
process in Van Vliet’s theory is resistance. Using their reformed identity and renewed 310 
positive self-image as ‘good’ or ‘normal’ people, some participants expressed stigma 311 
resistance through becoming an activist or supporter of other PLWH. Others 312 
expressed their resistance through reaching out to rejecting family members, 313 
deciding not to be ashamed, and widely disclosing their HIV status.  314 
Our findings regarding reforming identity reflect those of Aujoulat et al.’s study 315 
(Aujoulat, Marcolongo, Bonadiman, & Deccache, 2008), in which chronically ill 316 
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patients described a process through which they managed to resolve their identities 317 
as ‘people living with a disease’, not as ‘diseased people’. Aujoulat et al. describe the 318 
processes through which individuals come to terms with a disrupted ‘well’ or ‘normal’ 319 
identity, manage the threat to their security and identity which illness represents, and 320 
face the lack of coherence or meaning which often accompanies diagnosis (Aujoulat 321 
et al., 2008). This reflects our own data and the wider HIV literature, which highlights 322 
that resistance for PLWH involves re-negotiating control over health and illness 323 
(Brinsdon, Abel, & Desrosiers, 2017; Goudge et al., 2009). 324 
Our findings suggest that healthcare systems can play a role both in perpetuating 325 
and alleviating HIV-associated stigma. Research from South Africa also describes 326 
how women attending health care settings appreciated positive interactions with 327 
staff, while negative experiences further stigmatised (Okoror, BeLue, Zungu, Adam, 328 
& Airhihenbuwa, 2014). Recent research from Bangladesh demonstrates how a 329 
sexual and reproductive health rights training package administered to health care 330 
workers can reduce the stigma experienced by their patients. This study found that 331 
indicators of HIV-associated stigma among healthcare workers were reduced, 332 
alongside an increase in patient satisfaction with services (Geibel et al., 2017). In our 333 
study, the participants witnessed a working example of supportive, stigma-free care, 334 
and help to manage stigma through the provision of space to disclose and discuss 335 
openly. 336 
An alternative explanation for the shift we observed in how participants felt could be 337 
that participants adjusted to their diagnosis over time. However, this sample of 338 
participants had been diagnosed with HIV for a median of 3.5 years (IQR 1.3-5.2) 339 
and had been on ART for a median of 2.5 years (IQR 0.8-4.2), therefore it is unlikely 340 
that this is the sole explanation. It might also be that the intervention itself, rather 341 
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than trial participation, improved stigma resistance. However, the striking similarity 342 
between the changes described by both control and intervention arm participants 343 
suggests otherwise. There was no contamination in the trial; control arm participants 344 
were seen by different clinical nurses. Additionally, the participants repeatedly 345 
referred to ‘you’ (addressing the researcher) as the one who had helped them. 346 
A limitation of the study is that the concept of stigma emerged as an inductive theme 347 
during data analysis rather than being explored explicitly in the topic guides. Data on 348 
the experience of stigma and response to stigma was therefore not collected from all 349 
participants. However, despite this, stigma was a key feature of many patients’ 350 
experiences of trial participation, described by 25 of the 30 participants. Another 351 
limitation is that, due to the inclusion criteria for the wider trial, the findings represent 352 
the experiences of PLWH who have been on ART for more than a month and are 353 
experiencing non-acute moderate to severe pain or other symptoms. However, this 354 
does not negate the importance of the experiences of this patient group. Since 355 
interviews were conducted by the same researcher who implemented the study, 356 
some social desirability bias is possible. We chose to keep the same researcher for 357 
both study components because of her experience and skill in conducting palliative 358 
care research, as we believe this skill outweighed any potential bias.  Finally, the 359 
qualitative interviews necessarily took place after the trial had finished and so could 360 
be affected by recall bias.  361 
Our findings have direct implications for clinical care and research for HIV 362 
communities, highlighting the association between psychosocial care and increased 363 
resistance to HIV-associated stigma. Failing to tackle stigma is a significant threat to 364 
infection control, access to testing, adequate treatment, and healthcare utilisation. 365 
Stakeholders at all levels of HIV care provision should consider the potential effects 366 
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of increasing levels of compassion, communication and social support in the care 367 
they provide to help PLWH resist stigma. It may be possible to integrate this 368 
approach into other, more established roles that are included in recommendations 369 
for best practice, such as treatment navigators or peer educators (Simoni, 370 
Pantalone, Plummer, & Huang, 2007; Thompson et al., 2012).  371 
Future research is needed to explore whether the hypothesised shame resistance 372 
mechanisms of connecting, refocusing, accepting, understanding and resisting do 373 
indeed contribute to stigma resistance in PLWHA. Stigma should also be measured 374 
using a standardised outcome measure such as the PLWH Stigma Index, adapted 375 
and validated in each cultural setting, to enable cross-study and cross-country 376 
comparison and service evaluation (dos Santos, Kruger, Mellors, Wolvaardt, & van der 377 
Ryst, 2014; International Planned Parenthood Federation, 2008).  378 
The findings also have implications for researchers working with socially isolated or 379 
stigmatised groups, who should consider the beneficial effects of participating in 380 
research, which may be in addition to any overt therapeutic input, in study design. 381 
This has been discussed more fully elsewhere (Lowther et al., 2016). 382 
Resistance to HIV-associated stigma is possible, and can be encouraged through 383 
compassionate communication and social support. If these findings can be replicated 384 
at a larger scale and in different contexts, this affordable and life-affirming approach 385 
could have considerable public health and clinical significance for management of 386 
the HIV pandemic. 387 
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Table 1 Clinical and demographic characteristics of the sample (n=30) 563 
Mean age (years, sd) 39.1 (6.9) 
Gender (% female) 80% 
Partner status , yes N (%) 17 (56.7%) 
Number of children 
Mean (sd) 
Median (IQR) 
 
2.4 (1.4) 
2 (2-3) 
Number of financial dependents 
Mean (sd) 
Median (IQR) 
 
3.2 (2.0) 
3 (2-4) 
Education attainment N (%) 
None 
 4 years or less 
Primary education 
Secondary education 
Diploma 
 
3 (10.0%) 
2 (6.7%) 
15 (50.0%) 
10 (33.3) 
0 (0%) 
CD4 count at baseline, Mean (sd) 348.13 (273.75) 
Receiving TB treatment? Yes n (%) 5 (16.6%) 
Received an AIDS diagnosis? Yes n (%) 30 (100%) 
Owns a bicycle? Yes n (%) 8 (26.7%) 
Owns a fridge? Yes n (%) 7 (23.3%) 
Owns a television? Yes n (%) 18 (60%) 
Owns a car? Yes n (%) 2 (6.7%) 
Owns a radio? Yes n (%) 18 (60%) 
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Mental health summary score change 
on MOS-HIV MHSS 
 
Improving (increase of 10 points) 
Deteriorating (decrease of 10 points) 
Static (no change of 10 points or more) 
Control 
n(%) 
 
6 (60%) 
0 (0%) 
4 (40%) 
Intervention 
n(%) 
 
14 (70%) 
1 (5%) 
5 (25%) 
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Table 2 Experience of HIV-associated stigma 566 
Quote 
number 
Quote 
1 “Initially, I had a lot of [hesitates] … friends, but when I knew about my 
status I started fearing them – because I feared they [hesitates] might be 
discussing about me”. Woman, age 28, intervention arm ID 126 
2 “I was so afraid because in my entire life I never thought this disease 
would get me. I knew it was meant for some people with immoral 
behaviours within the community and I was living a straight upright life, 
even without a degree education.” Woman, 33 years, control arm ID 158 
3 “[They said:] ‘You went and took your own illness. I told [you about] your 
husband - leave him, he will infect you with that illness, he likes a lot of 
women - now you see? Now you see?’” Woman, 40 years, control arm ID 
133 
4 “The way they used to talk about me, that I have this illness, and then 
they started isolating me. At first we were together but when they knew I 
had that illness they started isolating me, and that brought on the 
thoughts. When I look around, I can’t find any companion.” Woman, 40 
years, control arm ID 133 
 567 
 568 
 569 
 570 
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Table 3 Effects of participation in the study 572 
Quote 
number 
Quote 
5 “Yeah, based on how we started, the way you showed me the importance, you 
enlightened me about this condition and the importance of my life. This made me 
to change and go back to my normal state and be like any other person.” Woman, 
39 years, intervention arm ID 106 
6  “When you used to ask me questions, I used to feel much free inside … I felt like a 
very normal person without any form of illness, I felt so good eh”. Woman, 54 
years, intervention arm ID 126 
7 “I started viewing myself like any other person, as you see me now, like am not 
sick at all. I stopped worrying about myself and focused.” Woman, 43 years, 
intervention arm ID 129 
8 “…because thinking back when I used to be so ill, I saw it wise to kill myself with a 
rat poison [laughing], mixing it with a glass of water and drink it all [laughing] … 
because there was no need staying on earth’s surface in so much pain and 
suffering, at times I felt like hanging myself… when I started coming here you 
[nurses] started advising me... since then I have been so close to God and never 
had a bad thought again. … I dumped the rat poison in a pit latrine.” Woman, 43 
years, intervention arm ID 129 
9 “I used to be soothed, such as being treated well, I mean I felt esteemed, that 
people here regarded me and treated me with respect”. Woman, 39 years, 
intervention arm ID 106 
10 “Now, I didn’t have anyone to talk to or someone to ask me, “How are you 
feeling, what do you think or how are you doing?” So when I came here I feel it 
really helped me because I found … [hesitates] that day, I found people who were 
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very free and they talked to me very nicely. The way I was received – I really 
appreciate.” Woman, 46 years, control arm ID 107 
11 “What I’d want to say is to appreciate you [the interviewer] for the service that I 
received here. I was treated so well till I started feeling like I’m really a human 
being. Indeed, this is place where you are treated with dignity to the point of 
appreciating yourself.” Man, 44 years, intervention arm ID 123 
12  “So many things have contributed to these changes, but the greatest of all is me 
accepting myself in this condition and appreciating that this is my new way of life; 
another thing is the way you handle patients. For instance, one may come here 
broken hearted and feeling down but you would encourage and give him the best 
so many things contributed to this change.” Woman 33 years, control arm ID 158 
13 “It has changed my thought, cleared my mind and my feelings also, I felt like one 
who matters in the society… I have changed and [the experience of participating 
in the study] made to accept myself as I am. It made my heart stronger and I 
proceeded on with my normal life.” Woman 50 years, intervention arm ID 135 
14 “I had understood and accepted myself as I am; I was never ashamed any more 
but rather very open.” Man, 43 years, control arm ID 97 
15 “I was only close to my brother amongst my family members and because I wasn’t 
open to him either, we never had a good relationship but during the study I 
changed. I could go to his house and explain my condition to him care free. So, 
our relationship has revived and we are free to each other.” Woman, 33 years, 
control arm ID 158  
16 “The first advice I received when they diagnosed me to be positive they told me 
that, “mum you have the virus and you don’t need to panic in front of people 
because they will realize you have it, all you need to do is behave normally, don’t 
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behave awkwardly and get rid of all the worries.” Woman, 54 years, intervention 
arm ID 126 
17 “The most important thing was … being able to express myself. To accept what 
has become of me and to say that this is what is happening but I can overcome it. 
This has been very nice and then a forum of expressing my innermost feelings and 
fears.” Woman, 41 years, intervention arm ID 134 
18 “I just love the way I was being questioned in a polite tone that made me to open 
up my heart. I love the way you handle me in a friendly nice way.” Woman, 33 
years, control arm ID 159 
19  “You helped by asking me several questions on what was affecting [me], I felt like 
someone was helping me to carry my burden.” Woman, 42 years, control, ID 130 
20 “It also helped me because when I started going there I used to be afraid but after 
coming here and got to be asked the questions, I started answering expressly, I 
found it to be of much help because I started feeling free.” Woman, 46 years, 
control arm ID 107 
21 “[Participating] gave me the courage even to stand in front of anyone to share 
with them about myself.... I have a very good relationship [with those in my 
community] because I have disclosed my status to them. They have even 
nicknamed me – you know me as [name] they call me a minister. And do you 
know it’s a minister in charge of what? Minister for viruses! And I have accepted 
it.” Woman, 36 years, control arm, ID 143 
22 I was scared when I first started this study, and my health was also not in a good 
condition when I started but as I came here for the discussions I started feeling 
ok, because I became free and started living my life as normal and when I told my 
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family about my health, they also joined hands in supporting me.” Woman 50 
years, intervention arm ID 135 
23 “About my experience here, let me say that you people helped me a lot, because 
right now I can go out and tell or teach someone or approach someone, telling 
them to go and know their statuses. …. Never mind they’re the very, same people 
who were speaking ill about me. Yeah and I still reach out to them, counselling 
them and once they agree, I take them up to there [to the hospital to test for 
HIV]”. Female, 36 years, control arm ID 143 
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